India and China Could Be On The Brink Of A Biosimilars Takeoff, Says One Biotech CEO
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Asia's giants - India and China - could see a Big Bang-like explosion of biotech- and biosimilar-focused start-ups given the right conditions over the next decade, including an infusion of capital from the West, according to the head of an Indian biopharmaceutical firm